GlassScriptPhysician profile
Jennifer L Tempest
NPI 1144866963
$1,101.65
in general payments reported to CMS, 2019-2025
13 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $113 · 2023: $246 · 2024: $54.98 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $264.61 | 2021-2023 | |
| Hologic Sales and Service, LLC | $217.45 | 2023-2025 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Novo Nordisk INC | $139.17 | 2021-2023 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $109.28 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $67.35 | 2023 | |
| Channel Medsystems, INC. | $63.31 | 2023 | |
| Astellas Pharma US INC | $51.85 | 2025 | Veozah |
| Boston Scientific Corporation | $50.42 | 2021-2024 | Solyx Sis System, Upsylon |
| Organon LLC | $39.98 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $30.43 | 2021-2023 | Gardasil 9 |
| Exeltis, USA INC. | $28.68 | 2024-2025 | Slynd |
| Pfizer INC. | $22.35 | 2025 | |
| Axonics, INC. | $16.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Tempest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.